Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital cites challenging consumer backdrop for Domino's

(Sharecast News) - Shore Capital has reiterated a 'buy' rating for Domino's Pizza ahead of its interim results next month, but said it was taking "a more cautious stance" given the subdued consumer backdrop. At the end of April, when Domino's last updated the market, the pizza delivery chain reported slower-than-expected like-for-like sales growth in the first quarter, up just 0.5%.

Following on from that, Shore Capital highlighted an unplanned trading update from bakery chain Greggs last week, which cited weak footfall in June due to the hot weather. While Domino's is less impacted by weather, since the majority of its orders take place in the evening, the broker reckons that the business is not completely immune to the challenges that Greggs has been facing.

Meanwhile, recent "persistent negative" consumer confidence figures from market research firm GfK, Shore Capital said, along with five straight months of decelerating family spending power, as shown by the Asda income tracker.

"Ahead of the Domino's H1 results next month, we take a more cautious outlook both in the current and outer years," the broker said as it cut its current-year EBITDA forecast from £150m to £144m.

"We believe there is still much to like, particularly in terms of loyalty potenital for increasing orders; however, we prefer to remain cautious ahead of the interim result."

Nevertheless, with the stock trading at an EV/EBITDA multiple of 11, which it still a discount to others in the sector, Shore Capital still sees upside from the current share price.

The stock was down 1.6% at 251.6p by 1238 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.